117 results
CORRESP
CHRS
Coherus Biosciences Inc
30 Dec 21
Correspondence with SEC
12:00am
”) are fundamentally different from normal, recurring research and development expenses. This determination is based primarily on the considerations discussed below … represents what the Company believes to be normal, recurring, cash operating expenses related to research and development necessary to operate its business
8-K
EX-99.1
CHRS
Coherus Biosciences Inc
6 May 21
Coherus BioSciences Reports First Quarter 2021 Financial Results and Immuno-oncology and Biosimilar Pipeline Progress
4:24pm
realignment of research and development resources toward immuno-oncology.
Non-GAAP net income for the first quarter of 2021 was $0.4 million, or $0.01 … expenses:
Cost of goods sold
Research and development
Selling, general and administrative
Total operating expenses
(Loss) Income from operations
Interest
8-K/A
EX-99.1
u25qr6rzcifxdr03
6 Nov 23
Report of Independent Registered Public Accounting Firm
6:07am
8-K/A
EX-99.2
kax4nv xbiq0f
6 Nov 23
Report of Independent Registered Public Accounting Firm
6:07am
8-K
EX-99.2
l6zch
4 Mar 24
Completion of Acquisition or Disposition of Assets
6:22am
8-K
EX-99.1
bm0nad87ul24wyg58w
8 Nov 21
Coherus BioSciences Reports Third Quarter 2021 Results
4:06pm
424B4
yar72x
6 Nov 14
Prospectus supplement with pricing info
12:00am